Home
DTIL
DTIL News

Latest Precision BioSciences Inc. (DTIL) News on November 4, 2025

Associated Press Finance

20 hours ago

Precision BioSciences: Q3 Earnings Snapshot

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Business Wire

20 hours ago

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Business Wire

4 days ago

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy

Simply Wall St.

4 days ago

Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happy

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?

Zacks

19 days ago

Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Business Wire

21 days ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Business Wire

a month ago

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Business Wire

a month ago

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Business Wire

2 months ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 06/30/2025

MT Newswires

4 months ago

US Equity Futures Rise Ahead of Powell Testimony

MT Newswires

4 months ago

Top Premarket Gainers

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Business Wire

4 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Will Tesla have to play catch up to Waymo's robotaxis?

Yahoo Finance Video

5 months ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys

Yahoo Finance

5 months ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

Statement by Minister Guilbeault on Portuguese Heritage Month

CNW Group

5 months ago

Statement by Minister Guilbeault on Portuguese Heritage Month

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

PR Newswire

5 months ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

GlobeNewswire

5 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

GlobeNewswire

5 months ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

Man Utd sign Brazil forward Cunha from Wolves

AFP

5 months ago

Man Utd sign Brazil forward Cunha from Wolves

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

Moneywise

5 months ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

GOBankingRates

5 months ago

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

3 International Vacations That Are Cheaper Than an iPhone

GOBankingRates

5 months ago

3 International Vacations That Are Cheaper Than an iPhone

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

GOBankingRates

5 months ago

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

This week in Trumponomics: Too bad TACO isn’t true

Yahoo Finance

5 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

The Guardian

5 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Yahoo Finance Video

5 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Benzinga

5 months ago

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Reuters

5 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Sidoti Events, LLC's Virtual May Micro-Cap Conference

ACCESS Newswire

5 months ago

Sidoti Events, LLC's Virtual May Micro-Cap Conference

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Zacks

6 months ago

Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates

Associated Press Finance

6 months ago

Precision BioSciences: Q1 Earnings Snapshot

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Business Wire

6 months ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Business Wire

6 months ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Business Wire

6 months ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Business Wire

6 months ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Business Wire

6 months ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

6 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

Zacks

7 months ago

DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up

MT Newswires

7 months ago

Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Business Wire

7 months ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks

7 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Business Wire

7 months ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Business Wire

7 months ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Business Wire

7 months ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire

8 months ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

MT Newswires

8 months ago

Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Business Wire

8 months ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Business Wire

8 months ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/21/2025

Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV

Clinical Trials Arena

8 months ago

Precision reports initial outcomes from Hepatitis B trial of PBGENE-HBV

Argus Research

8 months ago

Daily – Vickers Top Insider Picks for 02/20/2025

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Benzinga

9 months ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Business Wire

9 months ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 02/19/2025

Argus Research

9 months ago

Daily – Vickers Top Insider Picks for 02/18/2025

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Business Wire

9 months ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

MT Newswires

10 months ago

Precision BioSciences Shares Up After Upgrade From BMO Capital, Positive Date From Gene Therapy Study

MT Newswires

10 months ago

BMO Capital Upgrades Precision BioSciences to Outperform From Market Perform, Price Target is $34

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Business Wire

10 months ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Business Wire

10 months ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 01/03/2025

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 12/31/2024

Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial

Clinical Trials Arena

a year ago

Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Business Wire

a year ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences

Business Wire

a year ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Business Wire

a year ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates

Zacks

a year ago

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

a year ago

Precision BioSciences: Q3 Earnings Snapshot

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Business Wire

a year ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?

Zacks

a year ago

Precision BioSciences (DTIL) Surges 6.1%: Is This an Indication of Further Gains?

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Business Wire

a year ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Business Wire

a year ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Business Wire

a year ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Precision BioSciences to Report Q3 Earnings: What's in the Cards?

Zacks

a year ago

Precision BioSciences to Report Q3 Earnings: What's in the Cards?

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Business Wire

a year ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Business Wire

a year ago

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Business Wire

a year ago

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?

Zacks

a year ago

Cartesian Therapeutics, Inc. (RNAC) Moves 26.9% Higher: Will This Strength Last?

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Business Wire

a year ago

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

MT Newswires

a year ago

Precision BioSciences Submits Clinical Trial Applications for Hepatitis B Treatment

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Business Wire

a year ago

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

a year ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Precision BioSciences (DTIL) Could Surge 277.6%: Read This Before Placing a Bet

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Business Wire

a year ago

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock

Zacks

a year ago

Despite Fast-paced Momentum, Precision BioSciences (DTIL) Is Still a Bargain Stock

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Business Wire

a year ago

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Business Wire

a year ago

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade

Zacks

a year ago

Wall Street Analysts Believe Precision BioSciences (DTIL) Could Rally 307.93%: Here's is How to Trade

FDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment

Clinical Trials Arena

a year ago

FDA grants IND clearance for TG Therapeutics’ trial of multiple sclerosis treatment

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Business Wire

a year ago

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates

Zacks

a year ago

Precision BioSciences (DTIL) Tops Q2 Earnings and Revenue Estimates

Associated Press Finance

a year ago

Precision BioSciences: Q2 Earnings Snapshot

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Business Wire

a year ago

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Participate in Upcoming August Investor Conferences

Business Wire

a year ago

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Business Wire

a year ago

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Business Wire

a year ago

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Business Wire

a year ago

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Business Wire

a year ago

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

Business Wire

a year ago

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness

Share on Social Networks: